VIDEO: Verséa offerings target ocular wound healing, surface diseases

ByRob Sambursky, MD

ByAnthony DeFino

Fact checked byEamon N. Dreisbach

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Rob Sambursky, MD, president of Verséa Ophthalmics, discusses the company’s offerings for ocular wound healing and ocular surface diseases.

In addition to the Biovance and Biovance 3L Ocular allografts, Sambursky previewed Verséa’s tear-based point-of-care (T-POC) quantitative testing platform for diagnosing ocular surface diseases.

“Now we have the ability to not only to identify a disease, but stratify how bad it is,” he said. “We can then take that information and guide therapeutic decisions.”

Sambursky also previewed Verséa’s recent partnership with Eye Health America.

Published by:

Sources/Disclosures

Collapse

Source:

Sambursky R. AAO 2024 anterior segment showcase. Presented at: Eyecelerator@AAO; Oct. 17, 2024; Chicago

Disclosures: Sambursky reports being the president of Verséa Ophthalmics.

American Academy of Ophthalmology Meeting

Read more

VIDEO: Verséa offerings target ocular wound healing, surface diseases

Related Content